Nasopharyngitis (Common Cold) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Nasopharyngitis (Common Cold) – Drugs In Development, 2024 report and make more profitable business decisions.
Nasopharyngitis, also known as the common cold, is an infectious inflammatory condition that affects the throat and nasal passages. The virus can spread through droplets in the air when someone who is sick coughs, sneezes, or talks. Symptoms include sore throat, runny nose, sneezing, fatigue, headache, and loss of appetite. Risk factors include age and weakened immune system. Treatment includes pain relievers and decongestant medications.
The Nasopharyngitis (Common Cold) drugs in development market research report provide comprehensive information on the therapeutics under development for Nasopharyngitis (Common Cold), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasopharyngitis (Common Cold) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Nasopharyngitis (Common Cold) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 10 molecules, with 9 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Nasopharyngitis (Common Cold) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Nasopharyngitis (Common Cold) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Nasopharyngitis (Common Cold) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Adare Pharma SolutionsBai Shuo Beijing Pharmaceutical Technology Co Ltd
Charleston Laboratories Inc
Eurofarma Laboratorios SA
Firebrick Pharma Pty Ltd
Pfizer Inc
Tris Pharma Inc
Washington University in St Louis
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Nasopharyngitis (Common Cold) reports